|
|
|
市場調查報告書
商業交易與業界觀察:自體免疫病患與發炎性病患
Dealmaking and Industry Outlook: Autoimmune and Inflammatory Diseases
|
商業交易與業界觀察:自體免疫病患與發炎性病患 是由出版商Decision Resources, Inc.在2009年07月所出版的。
這份英文市場調查報告書包含43 Prices 價格從美金3450起跳。
本報告書介紹了自體免疫病患與發炎性病患市場銷售前25名的企業，在主要品牌的概述之外，尚有與製藥公司，生技企業的商業行為，商業戰略，業界將來的觀察等等內容。概述如下。
總綱
基本生物學的重要性
業界的規模與主要企業
商業行為分析200
- 交易額
- 最大案件
- 大生技企業、中堅製藥公司、大製藥公司的交易金額
- 不同病患的ｒ牽引
- 交易種類
- 追求資金與製品的大生技企業
- 生物製劑以外的交易
- 核酸技術交易
商務戰略
- 找尋標的物交易
- 企業併購
- 賣出
- 對生物製劑的熱情
- 藥劑循環
業界形成事件：2008∼2009年
- 統合大製藥公司的影響
- 安全性問題
- 生技企業企業要比對手先一步追求的事
促進業界成長的因素
- 自體免疫病患與發炎性病患領域的促進因素
- 自體免疫病患與發炎性病患領域的阻礙因素
業界觀察
圖表
AbstractFeaturing an analysis of more than 200 deals in this therapy area for 2007, 2008, and the fi rst fi ve months of 2009
Introduction
Better diagnostics, the means to treat earlier stage-disease,
disease-modifying therapies, and disease prevention are the holy grails of
autoimmune and infl ammatory disease drug development. However, basic science
and redundant biological pathways are holding back this therapy area. In this
report, we investigate the autoimmune and infl ammatory disease industry. We
analyze 200 deals in this therapy area for 2007, 2008, and the fi rst fi ve
months of 2009. We assess what types of deals companies are executing and what
business strategies they are deploying for future success. We discuss recent
industry-shaping events, industry drivers, and barriers that are holding back
this therapy area.
Questions Answered in This Report
- Analyzing deals opens up a window to a company' s business strategies.
What do the 200 deals related to autoimmune and infl ammatory diseases that
took place in 2007, 2008, and the fi rst fi ve months of 2009 indicate about
the business strategies of Big Biotech, Mid-Size Pharma, and Big Pharma? What
technologies are hot? What new targets were licensed or optioned?
- Three mega-mergers were announced in early 2009. What impact will these
deals have on this therapy area? Why did Pfi zer CEO Jeffrey Kindler think
that Wyeth was the right answer for Pfi zer? What trouble might Merck & Co.
Have with the Schering-Plough acquisition? What might prevent Roche from
achieving its goals in its acquisition of Genentech?
- The number of generics and branded generics is rising in some segments of
this therapy area. Which diseases are seeing an increase in these types of
agents and why? What do GlaxoSmithKline' s recent deals with Aspen Pharmacare
and Dr Reddy' s Laboratories indicate about this company' s current
strategies?
- Understanding biological pathways and discovering biomarkers is key to
future success in the autoimmune and infl ammatory disease markets. What
are the hurdles in this arena? What recent deals took place relating to
pharmacogenomics? What gene discoveries may help in at least one disease
area?
- Companies have a continued passion for biologics. What are the recent
deals in this area? What are the 16 licensed Mabs? The 11 recombinant
proteins? The 8 peptides?
- Companies are scouring early-stage technology opportunities for
breakthrough technologies and innovative product candidates. What are the
top fi ve most licensed technologies in our study period? What 37 nonbiologics
product deals took place? What were the 16 new targets?
Scope
- Therapy area: Diseases; market size, top 25 companies by worldwide
sales, major brands.
- 200 deals: Total deal volume; biobucks; 20 largest deals; Big
Biotech, Mid-Size Pharma and Big Pharma deals; most active disease areas; most
active companies; top fi ve deals by technology, outlicensing, divesting, new
targets, biological pathways; nucleic acid therapeutics; budesonide deals;
reformulations; inhaler issues; combination products.
- Business strategies: Inlicensing, outlicensing, divesting low
priority R&D programs, targeted acquisitions, benefi ts of a portfolio of
modest products, milestone-driven dealmaking, shared development risk,
emerging markets, generics markets, branded generics, life-cycle management,
optimizing the commercialization of off-patent drugs, a passion for biologics,
drug recycling and reformulations, fi xed-dose combinations.
- Industry-shaping events: Big Pharma consolidation, market entry,
safety issues, change of ownership issues, reverse mergers, tumor necrosis
factor-alpha (TNF-α) blockers, biotech' s fi nancial crisis.
- Industry outlook: Ten therapy area drivers; factors holding back
this therapy area; annual growth rates for specifi c disease areas; three
events that will invigorate the therapy area; two key harbingers of trouble to
come.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Importance of the Underlying Biology
- Industry Size and Major Players
- Analysis of 200 Deals
- Deal Volume
- Largest Deals
- Big Biotech, Mid-Size Pharma, and Big Pharma Deal Volumes
- Deals By Disease Category
- Types of Deals
- Big Biotech Looking for Money and Products
- Nonbiologic Product Deals
- Nucleic Acid Technology Deals
- Business Strategies
- King of Targeted Dealmaking
- Company Acquisitions: Maybe Not
- Divesting: Better Focus and Commercialization
- Passion for Biologics
- Drug Recycling
- Budesonide Story
- Drug Combination
- Industry-Shaping Events, 2008-2009
- Impact of Big Pharma Consolidation
- Safety Concerns
- Biotech Is Hurting
- Industry Drivers
- Ten Drivers of the Autoimmune and Infl ammatory Disease Therapy Area
- Factors Holding Back the Autoimmune and Infl ammatory Disease Industry
- Industry Outlook
Tables
- 1. Decision Resources Analysts' Input on the Current Status and Future
Directions of Autoimmune and Infl ammatory Disease Therapies
- 2. Autoimmune and Infl ammatory Diseases: Nonbiologic Product Deals,
2007-2009
- 3. Autoimmune and Infl ammatory Diseases: Nucleic Acid Therapeutics Deals,
2007-2009
- 4. Autoimmune and Infl ammatory Diseases: Antibody Deals, 2007-2009
- 5. Autoimmune and Infl ammatory Diseases: Peptide and Recombinant Protein
Deals, 2007-2009
- 6. Autoimmune and Infl ammatory Diseases: Drug Delivery and Formulation
Technology Deals, 2007-2009 .
Figures
- 1. Autoimmune and Infl ammatory Diseases: Top 25 Companies by Worldwide
Sales, 2008 and 2014
- 2. Autoimmune and Infl ammatory Diseases: Deal Volume Based on Potential
Deal Size, 2007-2009
- 3. Autoimmune and Infl ammatory Diseases: the Largest Deals, 2007-2009
- 4. Autoimmune and Infl ammatory Diseases: Big Pharma, Mid-Size Pharma, and
Big Biotech Deal Volume, 2007-2009
- 5. Deals in the Autoimmune and Infl ammatory Therapy Area by Categories of
Disease, 2007-2009
- 6. Types of Autoimmune and Infl ammatory Disease Deals, 2007-2009
- 7. NF-KB Pathway
- 8. Development Timeline for the Tumor Necrosis Factor-Alpha Blocker Humira
(adalimumab)
Mentioned in This Report
- Abbott
- Ablynx
- Actimis Pharmaceuticals
- Acusphere
- Adeona Pharmaceuticals
- affibody
- Airmid
- Alantos Pharmaceuticals
- Alba Therapeutics
- Albireo
- Alizyme Therapeutics
- Alkermes
- Alloksys Life Sciences
- Almirall
- Alnylam Pharmaceuticals
- Altana
- Amgen
- Amira Pharmaceuticals
- Anesiva
- AnGes MG
- Anthera Pharmaceuticals
- Antitope
- Aphios
- Arachnova Therapeutics
- Archemix
- Argenta Discovery
- Array BioPharma
- Arrow International
- Aspen Pharmacare
- Astellas Pharma
- AstraZeneca
- Atlantic Healthcare
- Biogen Idec
- Biolex
- BioLineRx
- Biolipox
- BioMarin Pharmaceuticals
- Bionomics
- Biotica
- Biovitrum
- Boehringer Ingelheim
- Brigham and Women' s Hospital
- Bristol-Myers Squibb
- Burrill & Co.
- CalciMedica
- Calistoga Pharmaceuticals
- Cambridge Antibody
- Technology
- Cambridge Biotechnology
- Can-Fite Biopharma
- Catalyst Biosciences
- CBR Institute for Biomedical
- Research
- Celgene
- Cell Signaling Technology
- Cellatope
- Celldex Therapeutics
- Cellzome
- Centocor
- Cephalon
- Cequent Pharmaceuticals
- CEVEC Pharmaceuticals
- Chiesi Farmaceutici
- Chugai
- Chroma Therapeutics
- Clinquest
- Codon Devices
- Compugen
- Cosmo
- Cypress Bioscience
- Daiichi-Sankyo
- Debiopharm
- Dongguan Kaifa Biomedicine
- Dr Falk Pharma
- Dr Reddy' s Laboratories
- Dr. Falk Pharma
- Dyax
|
 |
